# Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/immunogenicity-and-safety-of-a-recombinant-adenovirus-type-5-vectored-covid-19/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Fengcai Zhu,Xu-Hua Guan,Yu-Hua Li,Jian-Ying Huang,Tao Jiang,Li-Hua Hou,Jingxin Li,Bei-Fang Yang,Ling Wang,Wen-Juan Wang,Shi-Po Wu,Zhao Wang,Xiao-Hong Wu,Junjie Xu,Zhe Zhang,Si-Yue Jia,Busen Wang,Yi Hu,Jing‐Jing Liu,Jun Zhang,Xiao-Ai Qian,Qiong Li,Hong-Xing Pan,Hu-Dachuan Jiang,Peng Deng,Jin-Bo Gou,Xue-Wen Wang,Xue-Wen Wang,Xinghuan Wang,Xinghuan Wang,Wei Chen |
| Citations | 1,293 |
| DOI | 10.1016/s0140-6736(20)31605-6 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.thelancet.com/article/S0140673620316056/pdf |
| OpenAlex ID | https://openalex.org/W3042383115 |
| PMID | 32702299 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Xinghuan Wang](https://scholariq.org/researchers/xinghuan-wang/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Virus-based gene therapy research](https://scholariq.org/topics/virus-based-gene-therapy-research/)

## Paper topics

- [Virus-based gene therapy research](https://scholariq.org/topics/virus-based-gene-therapy-research/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.